null

SMILES: CCCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1

InChI Key: InChIKey=VQBUYPWHWZACJN-UHFFFAOYSA-N

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 413744   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Coagulation factor XI (Homo sapiens (Human))	BDBM413744 (4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...) Show SMILES CCCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 Show InChI InChI=1S/C26H25ClFN7O4/c1-3-4-5-22(26(38)31-16-7-8-17(25(29)37)20(28)11-16)34-13-23(39-2)19(12-24(34)36)18-10-15(27)6-9-21(18)35-14-30-32-33-35/h6-14,22H,3-5H2,1-2H3,(H2,29,37)(H,31,38)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.840	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...				US Patent US10421742 (2019) BindingDB Entry DOI: 10.7270/Q26M3967
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM413744 (4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...) Show SMILES CCCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 Show InChI InChI=1S/C26H25ClFN7O4/c1-3-4-5-22(26(38)31-16-7-8-17(25(29)37)20(28)11-16)34-13-23(39-2)19(12-24(34)36)18-10-15(27)6-9-21(18)35-14-30-32-33-35/h6-14,22H,3-5H2,1-2H3,(H2,29,37)(H,31,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem		n/a	n/a	2.10	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Coagulation factor XI (Homo sapiens (Human))	BDBM413744 (4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...) Show SMILES CCCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 Show InChI InChI=1S/C26H25ClFN7O4/c1-3-4-5-22(26(38)31-16-7-8-17(25(29)37)20(28)11-16)34-13-23(39-2)19(12-24(34)36)18-10-15(27)6-9-21(18)35-14-30-32-33-35/h6-14,22H,3-5H2,1-2H3,(H2,29,37)(H,31,38)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem		n/a	n/a	0.840	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM413744 (4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...) Show SMILES CCCCC(C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1-n1cnnn1 Show InChI InChI=1S/C26H25ClFN7O4/c1-3-4-5-22(26(38)31-16-7-8-17(25(29)37)20(28)11-16)34-13-23(39-2)19(12-24(34)36)18-10-15(27)6-9-21(18)35-14-30-32-33-35/h6-14,22H,3-5H2,1-2H3,(H2,29,37)(H,31,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.10	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...				US Patent US10421742 (2019) BindingDB Entry DOI: 10.7270/Q26M3967
					More data for this Ligand-Target Pair